 <h1>Lixisenatide Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to lixisenatide: subcutaneous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, lixisenatide may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking lixisenatide:</p><p>
<i>More common</i>
</p><ul>
<li>Anxiety</li>
<li>bloating</li>
<li>bluish or pale skin</li>
<li>blurred vision</li>
<li>chills</li>
<li>cold sweats</li>
<li>confusion</li>
<li>constipation</li>
<li>cough</li>
<li>darkened urine</li>
<li>depression</li>
<li>difficulty swallowing</li>
<li>dizziness</li>
<li>fainting</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>headache</li>
<li>hives, itching, redness, skin rash</li>
<li>increased hunger</li>
<li>indigestion</li>
<li>loss of appetite</li>
<li>nausea</li>
<li>nervousness</li>
<li>nightmares</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>seizures</li>
<li>shakiness</li>
<li>shortness of breath</li>
<li>slurred speech</li>
<li>tightness in the chest</li>
<li>troubled breathing</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Agitation</li>
<li>decreased urine output</li>
<li>hostility</li>
<li>irritability</li>
<li>lethargy</li>
<li>muscle twitching</li>
<li>rapid weight gain</li>
<li>stupor</li>
<li>swelling of the face, ankles, or hands</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking lixisenatide:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Diarrhea</li>
<li>loss of appetite</li>
<li>nausea or vomiting</li>
<li>stomach pain, fullness, or discomfort</li>
<li>indigestion</li>
<li>passing of gas</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of lixisenatide may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>belching</li>
<li>bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
<li>heartburn</li>
<li>pressure in the stomach</li>
<li>stomach discomfort, upset, or pain</li>
</ul><p>
<!-- end subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to lixisenatide: subcutaneous kit, subcutaneous solution</i></p><h3>General</h3><p>The most frequently reported adverse reactions were nausea, vomiting, headache, diarrhea, dizziness, and hypoglycemia.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 26.5%), vomiting (up to 10.5%)</p>
<p><b>Common</b> (1% to 10%): Dyspepsia, diarrhea, constipation, abdominal distension, abdominal pain, upper abdominal pain</p>
<p><b>Frequency not reported</b>: Pancreatitis<sup>[Ref]</sup></p><p>Gastrointestinal adverse reactions including nausea and vomiting were responsible for discontinuation of treatment in 4.3% of patients.  During clinical trials, the severity of gastrointestinal adverse reactions were graded as mild, moderate or severe in 64.2%, 32.3%, and 3.5% of cases, respectively.  The majority of reactions occurred during the first 3 weeks of treatment.  </p>
<p></p>
<p>During clinical trials, 21 cases of pancreatitis were reported including acute pancreatitis (n=3), pancreatitis (n=12), chronic pancreatitis (n=5), and edematous pancreatitis (n=1).  Of these cases, some had risk factors such as a history of cholelithiasis or alcohol abuse.  Fourteen cases of pancreatitis were reported in the comparator-treated.<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Pooled analysis of drug-treated patients has found that almost 70% were antibody positive at 24 weeks.  Of the antibody positive patients, those with the highest antibody concentrations (greater than 100 nmol/L) had attenuated glycemic responses.  Additionally, a higher incidence of allergic reactions and injection site reactions occurred in antibody positive patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Development of anti-lixisenatide antibodies (69.8%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypoglycemia (in combination with a sulfonylurea and/or a basal insulin)</p>
<p><b>Common</b> (1% to 10%): Hypoglycemia (in combination with metformin alone)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache</p>
<p><b>Common</b> (1% to 10%): Dizziness, somnolence<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Palpitations</p>
<p><b>Uncommon</b> (0.1% to 1%): Tachycardia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Cystitis<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site reactions including pain, pruritus, erythema<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Viral infection<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Influenza, upper respiratory tract infection<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Urticaria<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Anaphylactic reaction, angioedema, pruritus<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Adlyxin (lixisenatide)." sanofi-aventis, Bridgewater, NJ. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What is the difference between Soliqua and Xultophy?</li>
<li>How often do you need to inject Adlyxin?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about lixisenatide</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: incretin mimetics</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Lixisenatide Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Adlyxin</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Diabetes, Type 2</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to lixisenatide: subcutaneous kit, subcutaneous solution</i></p><h3>General</h3><p>The most frequently reported adverse reactions were nausea, vomiting, headache, diarrhea, dizziness, and hypoglycemia.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 26.5%), vomiting (up to 10.5%)</p><p><b>Common</b> (1% to 10%): Dyspepsia, diarrhea, constipation, abdominal distension, abdominal pain, upper abdominal pain</p><p><b>Frequency not reported</b>: Pancreatitis<sup>[Ref]</sup></p><p>Gastrointestinal adverse reactions including nausea and vomiting were responsible for discontinuation of treatment in 4.3% of patients.  During clinical trials, the severity of gastrointestinal adverse reactions were graded as mild, moderate or severe in 64.2%, 32.3%, and 3.5% of cases, respectively.  The majority of reactions occurred during the first 3 weeks of treatment.  </p><p></p><p>During clinical trials, 21 cases of pancreatitis were reported including acute pancreatitis (n=3), pancreatitis (n=12), chronic pancreatitis (n=5), and edematous pancreatitis (n=1).  Of these cases, some had risk factors such as a history of cholelithiasis or alcohol abuse.  Fourteen cases of pancreatitis were reported in the comparator-treated.<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Pooled analysis of drug-treated patients has found that almost 70% were antibody positive at 24 weeks.  Of the antibody positive patients, those with the highest antibody concentrations (greater than 100 nmol/L) had attenuated glycemic responses.  Additionally, a higher incidence of allergic reactions and injection site reactions occurred in antibody positive patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Development of anti-lixisenatide antibodies (69.8%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypoglycemia (in combination with a sulfonylurea and/or a basal insulin)</p><p><b>Common</b> (1% to 10%): Hypoglycemia (in combination with metformin alone)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache</p><p><b>Common</b> (1% to 10%): Dizziness, somnolence<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Palpitations</p><p><b>Uncommon</b> (0.1% to 1%): Tachycardia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Cystitis<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site reactions including pain, pruritus, erythema<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Viral infection<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Influenza, upper respiratory tract infection<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Urticaria<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Anaphylactic reaction, angioedema, pruritus<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Adlyxin (lixisenatide)." sanofi-aventis, Bridgewater, NJ. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What is the difference between Soliqua and Xultophy?</li>
<li>How often do you need to inject Adlyxin?</li>
</ul><h2>More about lixisenatide</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: incretin mimetics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Lixisenatide Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Diabetes, Type 2</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>